康希诺生物股份公司股东有哪些
康希诺生物股份公司股东
At CanSinoBIO, our main research and development focus is vaccines. We are a leading biopharmaceutical company with expertise in antigen discovery and vaccine development. Our goal is to provide innovative and effective vaccines to protect public health. In this article, we will explore the shareholders of CanSinoBIO, providing detailed information about each shareholder.
1. 天津市医药制造业
The first shareholder of CanSinoBIO is the Tianjin Pharmaceutical Manufacturing Industry. This shareholder has been with the company since its inception on January 13, 2009. They hold a significant stake in the company, with a total investment of 247.44 million RMB. As a shareholder, they play a crucial role in the strategic decision-making process and contribute to the overall growth and success of CanSinoBIO.
2. 上海千希睿企业管理合伙企业(有限合伙)
The second shareholder of CanSinoBIO is the Shanghai Qianxirui Enterprise Management Partnership (LP). This shareholder is an active participant in the company's affairs as an executive partner. Their involvement indicates their commitment to the success of CanSinoBIO and their belief in the company's potential. Their role includes contributing to key strategic decisions and supporting the overall growth of the company.
3. 上海君实生物医药科技股份有限公司
The third shareholder of CanSinoBIO is Shanghai Junshi Biosciences Co., Ltd. This company recently announced its intention to issue stocks and be listed on the Science and Technology Innovation Board (STAR Market). Their investment in CanSinoBIO underlines their confidence in the company's capabilities and potential. Their participation as a shareholder can bring new opportunities for collaboration and contribute to the overall development and expansion of CanSinoBIO.
4. The Goldman Sachs Group, Inc.
The Goldman Sachs Group, Inc. is another shareholder of CanSinoBIO. They recently experienced a change in their shareholding, with a decrease of 101.48 million shares. Their ongoing involvement as a shareholder reflects their continued interest and support for the company. The Goldman Sachs Group, Inc. is a renowned global investment banking and securities firm, and their participation can bring financial stability and expertise to CanSinoBIO.
5. 廖正芳
Liao Zhengfang is a significant shareholder of CanSinoBIO, as well as the director of Tianjin Qianrui Enterprise Management Partnership (LP) and Tianjin Qianyi Enterprise Management Partnership (LP). His involvement as a shareholder highlights his belief in the company's potential. Liao Zhengfang's expertise and experience in enterprise management can contribute to the overall growth and development of CanSinoBIO.
6. 彭山鑫城产业投资有限公司
彭山鑫城产业投资有限公司(Pengshan Xincheng Industrial Investment Co., Ltd.) is another shareholder of CanSinoBIO. They recently completed a reduction plan and decreased their shareholding by 7.1883 million shares, accounting for 1.30% of the total shares. This reduction plan indicates their strategic decision to adjust their shareholding in CanSinoBIO. Their continuous involvement as a shareholder reflects their long-term commitment to the company.
7. 上海三维
上海三维(Shanghai Sanwei) is one of the major shareholders of CanSinoBIO, holding 49.7971% of the company's equity. Their investment demonstrates their belief in the company's growth potential and long-term success. 上海三维's significant stake provides them with a strong influence in the decision-making process, contributing to the overall direction and strategy of CanSinoBIO.
In conclusion, CanSinoBIO has a diverse group of shareholders who play a crucial role in the company's growth and success. Their investments, expertise, and support contribute to the development of innovative vaccines and the protection of public health. With the collaboration and commitment of these shareholders, CanSinoBIO is well-positioned to continue its research and development efforts and make significant contributions to the field of biopharmaceuticals.